Q2 2026 Earnings

August 4, 2026

Versigent

Forward-Looking Statements

This presentation contains forward-looking statements that reflect, when made, Versigent's current views with respect to current events, certain investments and acquisitions, business plans and financial performance. Such forward-looking statements are subject to many risks, uncertainties and factors relating to Versigent's operations and business environment, which may cause the actual results of Versigent to be materially different from any future results, expressed or implied, by such forward-looking statements. All statements that address future operating, financial or business performance or Versigent's strategies or expectations are forward-looking statements. In some cases, you can identify these statements by forward-looking words such as "may," "might," "should," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Factors that could cause actual results to differ materially from these forward-looking statements include, but are not limited to, the following: disruptions in the supply of raw materials and other supplies integral to our products; future significant public health crises and other global health crises and the measures taken in response thereto; a prolonged recession and/or a downturn in global automotive sales; the volatile global economic environment and geopolitical conditions, including conditions affecting the credit market and global inflationary pressures; our reliance on relationships with collaborative partners and other third parties for product development and such parties' failure to perform; employee strikes and labor-related disruptions involving us or one or more of our customers affecting our operations; fluctuations in interest rates and foreign currency exchange rates; our failure to comply with the numerous laws and regulations to which we are subject; adverse developments affecting one or more of our suppliers; any adverse impact of legal proceedings and disputes in which we are involved; challenges to our historical and future tax positions by taxing authorities; an increase in our tax burden due to ongoing or future tax audits; our failure to attract and retain key salaried employees and management personnel; our failure to manage the transition to a standalone public company; and our failure to achieve some or all of the benefits expected from the Spin-Off. Additional factors are discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Versigent's filings with the Securities and Exchange Commission, including those set forth in the Company's Information Statement furnished with the Company's Registration Statement on Form 10-12B/A filed on March 6, 2026. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect Versigent. It should be remembered that the price of the ordinary shares and any income from them can go down as well as up. Versigent disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events and/or otherwise, except as may be required by law.

Use of Non-GAAP Financial Measures

In addition to its reported results calculated in accordance with U.S. GAAP, the Company has included in this presentation Adjusted Net Sales Growth, Adjusted EBITDA, Adjusted Net Income and Adjusted Diluted EPS, performance measures, and Free Cash Flow, Net Debt and Net Leverage Ratio, liquidity measures, that the Securities and Exchange Commission defines as "non-GAAP financial measures". Adjusted Net Sales Growth represents the change in reported net sales relative to the comparable period, excluding the impact on net sales from currency exchange and commodity movements. Adjusted EBITDA represents net income (loss) attributable to Versigent before depreciation and amortization (including asset impairments), interest expense, income tax (expense) benefit, net (loss) income attributable to noncontrolling interest, other income (expense), net, equity income (loss), net of tax, restructuring, separation costs related to the Spin-Off, other acquisition and portfolio project costs (which includes costs incurred to integrate acquired businesses and to plan and execute product portfolio transformation actions, including business and product acquisitions and divestitures) and other special items. Adjusted EBITDA margin represents Adjusted EBITDA as a percentage of net sales. Adjusted Net Income represents net (loss) income attributable to Versigent before amortization, restructuring, separation costs related to the Spin-Off, other acquisition and portfolio project costs (which includes costs incurred to integrate acquired businesses and to plan and execute product portfolio transformation actions, including business and product acquisitions and divestitures) and other special items, including the tax impact thereon. Adjusted Diluted EPS represents Adjusted Net Income divided by the weighted average number of diluted shares outstanding for the period. Free Cash Flow represents net cash provided by (used in) operating activities less capital expenditures. Net Debt represents total debt less cash and cash equivalents. Net Leverage Ratio represents Net Debt divided by the trailing 12 months of Adjusted EBITDA.

Management believes these non-GAAP financial measures are useful to both management and investors in their analysis of the Company's financial position, results of operations and liquidity. In particular, management believes Adjusted Net Sales Growth, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS and Free Cash Flow are useful measures in assessing the Company's ongoing financial performance that, when reconciled to the corresponding U.S. GAAP measure, provide improved comparability between periods through the exclusion of certain items that management believes are not indicative of the Company's core operating performance and that may obscure underlying business results and trends. Management also uses these non-GAAP financial measures for internal planning and forecasting purposes.

Such non-GAAP financial measures are reconciled to the most directly comparable U.S. GAAP financial measures in Appendix. Non-GAAP financial measures should not be considered in isolation or as a substitute for our reported results prepared in accordance with U.S. GAAP and, as calculated, may not be comparable to other similarly titled measures of other companies.

Business Priorities

Unlocking value for shareholders as an independent company

Further strengthen market leading position

- Increase share by leveraging full-service capabilities and best-in-class operating model
- Leverage scale and capabilities in Automotive and other high-value end markets

Continue to optimize cost structure

- Leverage design capabilities and tools to expand automation deployment
- Continue to optimize manufacturing footprint

Consistently deliver strong financial results

- Sustain Automotive growth and strategically augment in target end markets
- Leverage scale for strong free cash flow generation

Deliver incremental value through disciplined capital deployment

- Competitive dividend to shareholders, with excess cash towards share repurchases
- Invest in organic and inorganic growth opportunities

Q2 2026 Highlights

Advancing our strategy while delivering profitable growth and shareholder value

Strong Financial Performance

- Net Sales **+11%** YoY
  - Adjusted Net Sales Growth[1] **+5%** YoY
- Adjusted EBITDA[1] **$272M**, +25% YoY
  - Adjusted EBITDA[1] margin **11.1%**, +120 bps YoY
- Free Cash Flow[1] **$107M**

Commercial Momentum

- **$2.8B** Q2 bookings[2] across new and existing customers
- **39** launches globally across **22** customers in Q2
- Customer recognition, including **Podio Ferrari Excellence** Award

Adjacent Market Expansion

- Q2 production **launches** in key growth areas include:
  - Agriculture (Americas, EMEA)
  - Commercial Vehicles (EMEA)

Initiated Shareholder Returns

- Initiated quarterly dividend
  - **$0.13** per ordinary share
- **$250M** share repurchase authorization available

Versigent

(1) Non-GAAP measure. Refer to Appendix for further details and reconciliation to most directly comparable U.S. GAAP measure.
(2) Bookings represent estimated cumulative net sales associated with customer programs awarded during the period over their expected production lives. Estimates are based on current program content, volume and production life assumptions and are subject to change.

Q2 2026
Financial Results

Q2 2026 Financial Highlights

$ millions, except per share amounts	Q2 2026	Q2 2025	YoY	Commentary
Net Sales	**$2,444**	$2,206	***+11%***	• Growth achieved despite lower global automotive production • Includes ~200 bps favorable FX impact and ~400 bps favorable commodity pass-throughs
Adjusted Net Sales[1]	**$2,308**	n/a	***+5%***	• Growth driven by higher volumes in North America and Asia Pacific
Adjusted EBITDA[1] *Margin*	**$272** *11.1%*	$218 *9.9%*	***+25%*** *+120 bps*	• Reflects disciplined operating execution and higher volumes • Q2 2026 includes $7M IEEPA tariff refunds • Q2 2026 margin includes ~50 bps net headwind from FX and commodity related passthroughs
Adjusted Diluted EPS[1, 2]	**$1.92**	$1.89	***+2%***	• Q2 2026 net income attributable to Versigent of $118M • Q2 2026 adjusted ETR 27%
Free Cash Flow[1]	**$107**	$108	***(1)%***	• Strong operating performance and Adjusted EBITDA[1] growth • Q2 2026 CapEx of $51M supports high launch activity in H2 2026 • Q2 2026 includes $22M of separation-related costs

(1) Non-GAAP measure. Refer to Appendix for further details and reconciliation to most directly comparable U.S. GAAP measure.
(2) For periods prior to the Spin-Off, the denominator for Adjusted Diluted EPS was calculated using the 70.89 million Versigent ordinary shares outstanding immediately following the Apr 1 '26 Spin-Off.

Q2 Net Sales

$ millions



Regional Net Sales

Region	Net Sales	YoY	Adjusted* YoY
Americas	$1,095M	+11% YoY	+6% YoY
Asia Pacific	$825M	+24% YoY	+15% YoY
EMEA	$524M	(6)% YoY	(11)% YoY

*Adjusted Net Sales Growth[1]

Versigent

(1) Non-GAAP measure. Refer to Appendix for further details and reconciliation to most directly comparable U.S. GAAP measure.

Q2 Adjusted EBITDA[1]

$ millions
% = Adjusted EBITDA[1] Margin



(1) Non-GAAP measure. Refer to Appendix for further details and reconciliation to most directly comparable U.S. GAAP measure.

Q2 Free Cash Flow[1] and Financial Position

Free Cash Flow

$ millions	Q2 2026	Q2 2025	YoY
Adjusted EBITDA[1]	**$272**	*$218*	***$54***
Capital expenditures	(51)	*(42)*	*(9)*
Separation costs	(22)	*(2)*	*(20)*
Restructuring payments	(11)	*(10)*	*(1)*
Tax payments	(26)	*(30)*	*4*
Interest payments	(2)	*(1)*	*(1)*
Working capital & other	(53)	*(25)*	*(28)*
Free Cash Flow[1]	**$107**	*$108*	***$(1)***

Financial Position

Strong liquidity and leverage profile as of Jun 30 ’26:

- **$1.4B** total liquidity available
  - **$554M** cash on hand
  - **$850M** revolver undrawn
- Net Leverage Ratio[1] of **1.8x**

Free Cash Flow[1] Generation and Balance Sheet Strength Support Shareholder Returns

(1) Non-GAAP measure. Refer to Appendix for further details and reconciliation to most directly comparable U.S. GAAP measure.

Updated FY 2026 Financial Guidance

$ millions	Current FY 2026	Previous FY 2026 *(May 5 '26)*
Net Sales	**$9,400 – $9,600**	*$9,100 – $9,400*
Adjusted Net Sales Growth %[1,2]	*+2%*	*+2%*
Adjusted EBITDA[3]	**$950 – $1,030**	*$950 – $1,030*
Free Cash Flow[3]	**$200 – $300** *Includes ~$70M of separation-related costs*	$200 – $300 *Includes ~$70M of separation-related costs*

Raised and tightened Net Sales guidance based on higher commodity pass-throughs and FX impacts

Reaffirmed Adjusted EBITDA[3] and Free Cash Flow[3] guidance

(1) Forward-looking non-GAAP measure. Refer to Appendix for further details and reconciliation to most directly comparable U.S. GAAP measure.
(2) FY 2026 FX and commodity assumptions as follows: Copper = 6.00, USD/MXN = 17.50, EUR/USD = 1.16, USD/CNY = 6.80.
(3) Forward-looking non-GAAP measure. The Company does not provide a reconciliation of such forward-looking measure to the most directly comparable financial measure calculated and presented in accordance with U.S. GAAP because to do so would be potentially misleading and not practical given the difficulty of projecting event-driven transactional and other non-core operating items in any future period. The magnitude of these items, however, may be significant. Refer to Appendix for definitions of Non-GAAP financial measures.

Capital Allocation

Free Cash Flow[1]

~$1B

Cumulative FCF Generation
2026E to 2028E

Capital Allocation Framework

Capital Expenditures

- Target ~3% of annual net sales

Quarterly Dividend[2]

- $0.13 per share dividend declared on Aug 3 ‘26
  - Record date: Sept 4 ‘26; Payment date: Sept 18 ‘26

Share Repurchases

- $250M share repurchase authorization available

(1) Forward-looking non-GAAP measure. The Company does not provide a reconciliation of such forward-looking measure to the most directly comparable financial measure calculated and presented in accordance with U.S. GAAP because to do so would be potentially misleading and not practical given the difficulty of projecting event-driven transactional and other non-core operating items in any future period. The magnitude of these items, however, may be significant. Refer to Appendix for definitions of Non-GAAP financial measures.

(2) The declaration and payment of future dividends are subject to the discretion of the Company’s Board of Directors and will depend on the Company’s financial condition, results of operations, cash requirements, and other factors deemed relevant by the Board of Directors.

Summary

Creating Value Through Disciplined Execution

- Delivered strong second quarter results despite a dynamic industry backdrop
- Leveraging our scale, customer relationships, and operating discipline to drive profitable growth
- Raised and tightened FY 2026 net sales guidance and initiated a quarterly dividend, reflecting confidence in our outlook and disciplined capital allocation
- Executing today while investing in the capabilities that will drive future growth and value creation



Appendix

Supplemental Information

Non-GAAP Financial Measures (unaudited)

Adjusted Net Sales Growth – Adjusted Net Sales Growth is presented as a supplemental measure of the Company's financial performance which management believes is useful to investors in assessing the Company's ongoing financial performance that, when reconciled to the corresponding U.S. GAAP measure, provides improved comparability between periods through the exclusion of certain items that management believes are not indicative of the Company's core operating performance and which may obscure underlying business results and trends. Our management utilizes Adjusted Net Sales Growth in its financial decision-making process, to evaluate performance of the Company and for internal reporting, planning and forecasting purposes. Adjusted Net Sales Growth is defined as the change in reported net sales relative to the comparable period, excluding the impact on net sales from foreign currency and commodity movements. Not all companies use identical calculations of Adjusted Net Sales Growth, therefore this presentation may not be comparable to other similarly titled measures of other companies.

Adjusted EBITDA – Adjusted EBITDA is presented as a supplemental measure of the Company's financial performance which management believes is useful to investors in assessing the Company's ongoing financial performance that, when reconciled to the corresponding U.S. GAAP measure, provides improved comparability between periods through the exclusion of certain items that management believes are not indicative of the Company's core operating performance and which may obscure underlying business results and trends. Our management utilizes Adjusted EBITDA in its financial decision-making process, to evaluate performance of the Company and for internal reporting, planning and forecasting purposes. Adjusted EBITDA is defined as net income (loss) attributable to Versigent before depreciation and amortization (including asset impairments), interest expense, income tax (expense) benefit, net (loss) income attributable to noncontrolling interest, other income (expense), net, equity income (loss), net of tax, restructuring, separation costs related to the Spin-Off, other acquisition and portfolio project costs (which includes costs incurred to integrate acquired businesses and to plan and execute product portfolio transformation actions, including business and product acquisitions and divestitures) and other special items. Not all companies use identical calculations of Adjusted EBITDA, therefore this presentation may not be comparable to other similarly titled measures of other companies. Adjusted EBITDA margin represents Adjusted EBITDA as a percentage of net sales.

Adjusted Net Income and Adjusted Diluted EPS – Adjusted Net Income and Adjusted Diluted EPS, which are non-GAAP financial measures, are presented as supplemental measures of the Company's financial performance which management believes are useful to investors in assessing the Company's ongoing financial performance that, when reconciled to the corresponding U.S. GAAP measure, provide improved comparability between periods through the exclusion of certain items that management believes are not indicative of the Company's core operating performance and which may obscure underlying business results and trends. Management utilizes Adjusted Net Income and Adjusted Diluted EPS in its financial decision-making process, to evaluate performance of the Company and for internal reporting, planning and forecasting purposes. Adjusted Net Income represents net (loss) income attributable to Versigent before amortization, restructuring, separation costs related to the Spin-Off, other acquisition and portfolio project costs (which includes costs incurred to integrate acquired businesses and to plan and execute product portfolio transformation actions, including business and product acquisitions and divestitures) and other special items, including the tax impact thereon. Adjusted Diluted EPS is defined as Adjusted Net Income divided by the weighted average number of diluted shares outstanding, for the period. Not all companies use identical calculations of Adjusted Net Income and Adjusted Diluted EPS, therefore this presentation may not be comparable to other similarly titled measures of other companies.

Free Cash Flow – Free Cash Flow is presented as a supplemental measure of the Company's liquidity, which is consistent with the basis and manner in which management presents financial information for the purpose of making internal operating decisions, evaluating its liquidity and determining appropriate capital allocation strategies. Management believes this measure is useful to investors to understand how the Company's core operating activities generate and use cash. Free Cash Flow is defined as net cash provided by (used in) operating activities less capital expenditures. Not all companies use identical calculations of Free Cash Flow, therefore this presentation may not be comparable to other similarly titled measures of other companies. The calculation of Free Cash Flow does not reflect cash used to service debt, pay dividends or repurchase shares and therefore, does not necessarily reflect funds available for investment or other discretionary uses.

Net Debt and Net Leverage Ratio – Net Debt and Net Leverage Ratio are presented as supplemental measures of the Company's liquidity, which is consistent with the basis and manner in which management presents financial information for the purpose of making internal operating decisions, evaluating its liquidity and determining appropriate capital allocation strategies. Net Debt is defined as total debt less cash and cash equivalents. Net Leverage Ratio is defined as Net Debt divided by the trailing 12 months of Adjusted EBITDA. We believe that Net Debt and Net Leverage Ratio are meaningful measures of financial condition as they are commonly used by management, investors and creditors to assess capital structure risk. Not all companies use identical calculations of Net Debt and Net Leverage Ratio, therefore this presentation may not be comparable to other similarly titled measures of other companies.

YTD Results

$ millions, except per share amounts	YTD 2026	YTD 2025	YoY
Net Sales	**$4,656**	$4,230	***+10%***
Adjusted Net Sales[1]	**$4,398**	n/a	***+4%***
Adjusted EBITDA[1]	**$475**	$416	***+14%***
Margin	*10.2%*	*9.8%*	*+40 bps*
Adjusted Diluted EPS[1, 2]	**$3.98**	$3.51	***+13%***
Free Cash Flow[1]	**$77**	$111	***(31)%***

(1) Non-GAAP measure. Refer to Supplemental Information included herein for further details and reconciliation to most directly comparable U.S. GAAP measure.

(2) For periods prior to the Spin-Off, the denominator for Adjusted Diluted EPS was calculated using the 70.89 million Versigent ordinary shares outstanding immediately following the Apr 1 '26 Spin-Off.

YTD Net Sales



(1) Non-GAAP measure. Refer to Supplemental Information included herein for further details and reconciliation to most directly comparable U.S. GAAP measure.

Regional Net Sales

Americas

		Adjusted*
$2,059M	+11% YoY	+6% YoY

Asia Pacific

		Adjusted*
$1,564M	+20% YoY	+13% YoY

EMEA

		Adjusted*
$1,033M	(3)% YoY	(11)% YoY

*Adjusted Net Sales Growth[1]

Versigent

YTD Adjusted EBITDA[1]



Versigent

(1) Non-GAAP measure. Refer to Supplemental Information included herein for further details and reconciliation to most directly comparable U.S. GAAP measure.

YTD Free Cash Flow[1]

$ millions	YTD 2026	YTD 2025	YoY
Adjusted EBITDA[1]	**$475**	*$416*	***$59***
Capital expenditures	(117)	*(79)*	*(38)*
Separation costs	(48)	*(7)*	*(41)*
Restructuring payments	(37)	*(28)*	*(9)*
Tax payments	(50)	*(57)*	*7*
Interest payments	(3)	*(2)*	*(1)*
Working capital & other	(143)	*(132)*	*(11)*
Free Cash Flow[1]	**$77**	*$111*	***$(34)***

Versigent

(1) Non-GAAP measure. Refer to Supplemental Information included herein for further details and reconciliation to most directly comparable U.S. GAAP measure.

Reconciliation of Net Sales to Adjusted Net Sales Growth

		Q2 2026	YTD 2026
Global	Reported net sales YoY % change	11%	10%
	Less: impact of foreign currency movements	(2)%	(2)%
	Less: impact of commodity movements	(4)%	(4)%
	Adjusted Net Sales Growth	**5%**	**4%**
Americas	Reported net sales YoY % change	11%	11%
	Less: impact of foreign currency and commodity movements	(5)%	(5)%
	Adjusted Net Sales Growth	**6%**	**6%**
Asia Pacific	Reported net sales YoY % change	24%	20%
	Less: impact of foreign currency and commodity movements	(9)%	(7)%
	Adjusted Net Sales Growth	**15%**	**13%**
EMEA	Reported net sales YoY % change	(6)%	(3)%
	Less: impact of foreign currency and commodity movements	(5)%	(8)%
	Adjusted Net Sales Growth	**(11)%**	**(11)%**

		FY 2026 Guidance Midpoint
Global	Reported net sales YoY % change	8%
	Less: impact of foreign currency and commodity movements	(6)%
	Adjusted Net Sales Growth	**2%**

Reconciliation of Net Income Attributable to Versigent to EBITDA and Adjusted EBITDA and Net Leverage Ratio

$ millions	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	TTM Jun 2026	YTD 2026	YTD 2025
Net income attributable to Versigent	107	109	217	78	118	522	196	202
Interest expense[1]	1	–	–	5	36	41	41	3
Income tax (benefit) expense	21	54	(110)	(9)	46	(19)	37	50
Net (loss) income attributable to noncontrolling interest	5	4	8	3	(2)	13	1	6
Depreciation and amortization	59	55	61	61	51	228	112	111
EBITDA	**193**	**222**	**176**	**138**	**249**	**785**	**387**	**372**
Other expense, net[1]	–	–	3	1	6	10	7	1
Equity income, net	(3)	(3)	(2)	(4)	(5)	(14)	(9)	(8)
Restructuring	25	21	24	46	–	91	46	41
Separation costs and other special items	2	7	28	26	22	83	48	7
Net gain on lease terminations	–	–	–	(4)	–	(4)	(4)	–
Other acquisition and portfolio project costs	1	1	–	–	–	1	–	3
Adjusted EBITDA	**218**	**248**	**229**	**203**	**272**	**952**	**475**	**416**
Total debt						2,224		
Less: cash and cash equivalents						(554)		
Net Debt						**1,670**		
Net Leverage Ratio						**1.8x**		
Memo:								
Net sales	2,206	2,286	2,302	2,212	2,444	9,244	4,656	4,230
Net income margin	*4.9%*	*4.8%*	*9.4%*	*3.5%*	*4.8%*	*5.6%*	*4.2%*	*4.8%*
Adjusted EBITDA Margin	*9.9%*	*10.8%*	*9.9%*	*9.2%*	*11.1%*	*10.3%*	*10.2%*	*9.8%*

(1) Prior period amounts were reclassified to conform to current period presentation.

Reconciliation of Net Income Attributable to Versigent to Adjusted Net Income and Adjusted Diluted EPS

$ millions, except per share amounts	Q2 2026	Q2 2025	YTD 2026	YTD 2025
Net income attributable to Versigent	118	107	196	202
Adjusting items:				
Amortization	–	1	1	1
Restructuring	–	25	46	41
Separation costs	22	2	48	7
Other acquisition and portfolio project costs	–	1	–	3
Asset impairments	–	3	7	3
Net gain on lease terminations	–	–	(4)	–
Pension curtailment and settlement losses	2	–	6	–
Separation-related interest expense	–	–	2	–
Tax impact of adjusting items[1]	(4)	(5)	(18)	(8)
Adjusted Net Income	**138**	**134**	**284**	**249**
Weighted average number of diluted shares outstanding[2]	71.88	70.89	71.39	70.89
Diluted earnings per share attributable to Versigent	1.64	1.51	2.75	2.85
Adjusted Diluted EPS	**1.92**	**1.89**	**3.98**	**3.51**

(1) Represents the income tax impacts of the adjustments made for amortization, restructuring and other special items by calculating the income tax impact of these items using the appropriate tax rate for the jurisdiction where the charges were incurred.

(2) For periods prior to the Spin-Off, the denominator for Adjusted Diluted EPS was calculated using the 70.89 million Versigent ordinary shares outstanding immediately following the Apr 1 '26 Spin-Off.

Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow

$ millions	Q2 2026	Q2 2025	YTD 2026	YTD 2025
Net cash provided by operating activities	158	150	194	190
Capital expenditures	(51)	(42)	(117)	(79)
Free Cash Flow	**107**	**108**	**77**	**111**

Versigent

Versigent